Confirm candidacy
Confirm whether complete cytoreductive surgery is achievable in your case.
Specialized Unit
Peritoneal Carcinomatosis of Colorectal Origin
At Quenet-Torrent Institute, we treat peritoneal carcinomatosis of colorectal origin with complete cytoreductive surgery, with or without HIPEC, in carefully selected patients and always within a multidisciplinary environment.
CONTACT SPECIALISTNeed to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon
-
EXTENSIVE EXPERIENCE +20,000 surgeries performed
-
LATEST TECHNOLOGY in surgical strategy
-
PERSONALIZED CARE First contact within 24/48h
Schedule your consultation with a specialist
What is colorectal peritoneal carcinomatosis?
Colorectal peritoneal carcinomatosis occurs when cancer cells from the colon or rectum spread to the peritoneal surface. It is diagnosed in approximately 10-15% of colorectal cancer patients, either synchronously at initial diagnosis or as a recurrence after treatment.
Historically considered a terminal condition, today we know that complete cytoreductive surgery (CC0), sometimes combined with HIPEC, can achieve 5-year survival of 30-40% in properly selected patients — results significantly superior to systemic chemotherapy alone.
The key factor is strict patient selection based on peritoneal disease extent (PCI), functional status, tumor biology, and response to systemic treatments.
Why request a second opinion for colorectal carcinomatosis?
Requesting a second opinion can reveal treatment options not initially considered.
Evaluate the PRODIGE 7 context
Understand whether HIPEC adds benefit in your specific situation based on current evidence.
PCI assessment
Obtain an expert evaluation of your peritoneal disease index and resectability.
Clinical trials
Consider participation in clinical trials with innovative perioperative strategies.
A specialized evaluation can change the prognosis in selected patients.
How do we treat colorectal carcinomatosis?
Treatment is based on complete cytoreduction combined with systemic and locoregional strategies tailored to each patient.
Neoadjuvant chemotherapy
Systemic treatment to evaluate tumor biology and select patients with chemosensitive disease.
Complete cytoreductive surgery (CC0)
Removal of all visible peritoneal disease — the most critical prognostic factor.
HIPEC (selected cases)
Hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin C in individualized cases.
Adjuvant chemotherapy
Postoperative systemic treatment according to molecular profile and risk stratification.
Patient selection is strict and based on multiple clinical, radiological, and pathological factors.
Our Technology
Technology for treating colorectal carcinomatosis
Precise diagnostic and surgical technology ensures the best possible patient selection and outcomes.
Staging laparoscopy
Direct PCI evaluation and resectability assessment before committing to open surgery.
PET-CT
Detection of extra-abdominal disease that would contraindicate surgery.
Automated HIPEC equipment
Precise thermal and flow control during perfusion when indicated.
Multidisciplinary tumor board
All cases discussed in a specialized committee with surgeons, oncologists, and radiologists.
WHY CHOOSE US?
Experience in colorectal carcinomatosis
Quenet-Torrent Institute offers a comprehensive approach, with teams specialized in advanced peritoneal disease.
Experience in Complex Cases
We specialize in treating advanced and metastatic cancer, using innovative techniques that other teams do not offer.
Comprehensive Multidisciplinary Approach
We form a team around you with surgeons, oncologists, radiologists, nutritionists, and psychologists, all working together for your cure.
Research and Innovation
We stay up to date with the latest scientific advances, allowing us to apply innovative treatments with better results.
State-of-the-Art Technology
We have facilities equipped with the most current medical technology, allowing us to perform high-precision procedures with less impact on the body.
Personalized and Close Care
We care about each patient as a person. We listen, support, and guide every step of the way.
Our Team
Colorectal carcinomatosis specialists
Every physician at Quenet-Torrent Institute is a recognized expert in their field, committed to each patient's well-being.
Dr. François Quenet
Oncological Surgeon
View doctor"Internationally renowned surgeon, expert in gastrointestinal and hepatobiliary tumors. Recognized for his precision in highly difficult surgeries."
Dr. Juan José Torrent
Oncological Surgeon
View doctor"Specialist in gynecological tumors and peritoneal carcinomatosis. A reference in complex and personalized oncological surgery."
Frequently asked questions about colorectal carcinomatosis
Answers to the most common questions about diagnosis, treatment, and prognosis.
Are all patients with colorectal carcinomatosis candidates for surgery?
No. Strict selection is required: limited PCI, good functional status (ECOG 0-1), possibility of complete cytoreduction, and absence of unresectable extra-peritoneal.
What is the significance of the PRODIGE 7 study?
PRODIGE 7 demonstrated that complete cytoreductive surgery is the most important factor for survival. HIPEC adds benefit in selected cases but does not replace quality.
When is HIPEC indicated in colorectal carcinomatosis?
The indication for HIPEC is individualized. It may benefit patients with complete cytoreduction, especially those with moderate PCI and no contraindications to.
What is the Peritoneal Carcinomatosis Index (PCI)?
The PCI quantifies the extent of peritoneal disease (0-39 points). A low PCI (<15-20) is associated with better prognosis and higher probability of compl.
What survival can be expected after surgery?
With complete cytoreduction (CC0), 5-year survival ranges from 30-40% in selected series — significantly better than systemic chemotherapy alone Outcomes depend on histology, PCI score, and completeness of cytoreduction.
Where can I receive this treatment safely?
In specialized centers with experience in peritoneal surface malignancies, like Quenet-Torrent Institute Chemotherapy complements surgery to optimise overall oncological control.
Easy Contact
Need to speak with a specialist?
Complete the form and schedule your appointment to speak directly with the surgeon.